| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | CD22; SIGLEC2; B-cell receptor CD22; B-lymphocyte cell adhesion molecule; BL-CAM; Sialic acid-binding Ig-like lectin 2; Siglec-2; T-cell surface antigen Leu-14; CD antigen CD22 |
| Entrez GeneID | 933 |
| WB Predicted band size | Calculated MW: 95 kDa; Observed MW: 140 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Recombinant protein of human CD22 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是3篇关于CD22抗体的代表性文献摘要(基于公开研究数据，具体内容请以原文为准)：
---
1. **文献名称**: *"Epratuzumab, a humanized anti-CD22 antibody, in autoimmune diseases: an update"*
**作者**: Carnahan J. et al.
**摘要**: 该综述总结了抗CD22单抗Epratuzumab在系统性红斑狼疮(SLE)等自身免疫病中的临床试验结果，证明其通过调节B细胞活性降低炎症反应，且安全性优于传统免疫抑制剂。
2. **文献名称**: *"CD22 regulates B cell receptor signal transduction in human B cells"*
**作者**: Nitschke L. et al.
**摘要**: 通过基因敲除实验揭示CD22作为B细胞受体(BCR)共受体的抑制作用，其通过招募SHP-1磷酸酶负向调控BCR信号通路，为靶向CD22的免疫疗法提供机制依据。
3. **文献名称**: *"Antibody-drug conjugates targeting CD22 exhibit potent anti-leukemic activity"*
**作者**: DiJoseph J.F. et al.
**摘要**: 报道了一种CD22靶向抗体药物偶联物(ADC)在B细胞急性淋巴细胞白血病(B-ALL)模型中的疗效，证明其通过递送细胞毒性药物卡奇霉素实现肿瘤细胞特异性杀伤。
---
如需具体文献DOI或更新研究，建议通过PubMed或Google Scholar以“CD22 antibody”、“CD22-targeted therapy”为关键词检索。
CD22. a transmembrane glycoprotein belonging to the sialic acid-binding immunoglobulin-like lectin (Siglec) family, is predominantly expressed on mature B cells. It functions as a inhibitory co-receptor for the B-cell receptor (BCR), modulating B-cell activation, survival, and differentiation. CD22's restricted expression on B-lineage cells and high prevalence in B-cell malignancies, such as non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL), make it an attractive therapeutic target.
CD22-targeting antibodies emerged in the 1990s, with early candidates like epratuzumab (a naked antibody) showing modest efficacy in autoimmune diseases and NHL. Advancements led to antibody-drug conjugates (ADCs), such as inotuzumab ozogamicin, which delivers cytotoxic payloads to CD22+ cancer cells, approved for relapsed/refractory ALL. Bispecific antibodies and CAR-T therapies incorporating anti-CD22 single-chain fragments are under investigation to enhance specificity and overcome resistance.
Challenges include antigen modulation (CD22 internalization post-antibody binding) and heterogeneous CD22 expression in tumors. Current research focuses on combination therapies, novel ADC linkers/payloads, and dual-targeting strategies to improve outcomes. Despite hurdles, CD22 remains a pivotal target in precision oncology for B-cell disorders.
×
